Ricardo Becker

Mr. Ricardo Becker

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2023 in Revista Brasileira de Ortopedia
Verified
Journal Article
Open access
PDF file
AGAlex Guedes
Alex Guedes
RBRicardo Becker
Ricardo Becker
LTLuiz Eduardo Moreira Teixeira
Luiz Eduardo Moreira Teixeira
Resumo: O mieloma múltiplo (MM) constitui neoplasia maligna de origem hematológica caracterizada pela proliferação desregulada e clonal de plasmócitos na medula óssea; estas células produzem e secretam imunoglobulina monoclonal anômala, ou um fragmento desta, denominado proteína M. As manifestações clínicas do MM decorrem da proliferação destes plasmócitos, da produção excessiva de imunoglobulina monoclonal e da supressão da imunidade humoral normal, levando à hipercalcemia, destruição óssea, insuficiência renal, supressão da hematopoiese e da imunidade humoral, aumentando o risco para o desenvolvimento de infecções. O aumento na expectativa de vida da população mundial levou a concomitante incremento na prevalência do MM, patologia que habitualmente acomete a população idosa. O objetivo desta revisão é atualizar o leitor sobre a epidemiologia, critérios diagnósticos, diagnóstico diferencial com outras gamopatias monoclonais, tratamento sistêmico e prognóstico do MM.

15 June 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
RBRicardo Becker
Ricardo Becker
LGLauro J. Gregianin
Lauro J. Gregianin
CGCarlos R. Galia
Carlos R. Galia
RFReynaldo Jesus-Garcia Filho
Reynaldo Jesus-Garcia Filho
ETEduardo A. Toller
Eduardo A. Toller
ABAlgemir Lunardi Brunetto
Algemir Lunardi Brunetto
Relapse in localized Ewing sarcoma patients has been a matter of concern regarding poor prognosis. Therefore, we investigated the impact of local control modality (surgery, surgery plus radiotherapy, and radiotherapy) on clinical outcomes such as survival and recurrence in patients with non-metastatic Ewing sarcoma treated on the first Brazilian Collaborative Group Trial of the Ewing Family of Tumors (EWING1). Seventy-three patients with localized Ewing sarcoma of bone aged < 30 years were included. The treating physicians defined the modality of local control based on the recommendations of the coordinating center and the patient and tumor characteristics. Possible associations of local control modality with local failure (LF), disease-free survival (DFS), event-free survival (EFS), overall survival (OS), and clinical characteristics were analyzed. Mean patient age was 12.8 years (range, 2 to 25 years) and median follow-up time was 4.5 years (range, 2.3 to 6.7 years). Forty-seven patients underwent surgery, 13 received radiotherapy, and 13 received both. The 5-year EFS, OS, and DFS for all patients was 62.1%, 63.3%, and 73.1%, respectively. The 5-year cumulative incidence (CI) of LF was 7.6% for surgery, 11.1% for radiotherapy, and 0% for postoperative radiotherapy (PORT) (p = 0.61). The 5-year EFS was 71.7% for surgery, 30.8% for radiotherapy, and 64.1% for PORT (p = 0.009). There was a significant effect of local control modality on EFS and OS in the study. Surgery and PORT modalities yielded very close results. The group treated with radiotherapy alone had considerably worse outcomes. This may be confounded by greater risk factors in these patients. There was no significant effect of local control modality on the CI of LF and DFS.

19 July 2023 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
DSDavid Slawaska-Eng
David Slawaska-Eng
AGAaron Gazendam
Aaron Gazendam
JKJoseph Kendal
Joseph Kendal
PSPatricia Schneider
Patricia Schneider
RBRicardo Becker
Ricardo Becker
OIon behalf of the PARITY Investigators
on behalf of the PARITY Investigators
Background: The specific risk factors for surgical site infection (SSI) in orthopaedic oncology patients undergoing endoprosthetic reconstruction have not previously been evaluated in a large prospective cohort. In the current study, we aimed to define patient- and procedure-specific risk factors for SSI in patients who underwent surgical excision and endoprosthetic reconstruction for lower-extremity bone or soft-tissue tumors using the prospectively collected data of the Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) trial. Methods: PARITY was a multicenter, blinded, randomized controlled trial with a parallel 2-arm design that aimed to determine the effect of a long duration (5 days) versus short duration (24 hours) of postoperative prophylactic antibiotics on the rate of SSI in patients undergoing surgical excision and endoprosthetic reconstruction of the femur or tibia. In this secondary analysis of the PARITY data, a multivariate Cox proportional hazards regression model was constructed to explore predictors of SSI within 1 year postoperatively. Results: A total of 96 (15.9%) of the 604 patients experienced an SSI. Of the 23 variables analyzed in the univariate analysis, 4 variables achieved significance: preoperative diagnosis, operative time, volume of muscle excised, and hospital length of stay (LOS). However, only hospital LOS was found to be independently predictive of SSI in the multivariate regression analysis (hazard ratio per day = 1.03; 95% confidence interval = 1.01 to 1.05; p < 0.001). An omnibus test of model coefficients demonstrated that the model showed significant improvement over the null model (χ2 = 78.04; p < 0.001). No multicollinearity was found. Conclusions: This secondary analysis of the PARITY study data found that the only independent risk factor for SSI on multivariate analysis was hospital LOS. It may therefore be reasonable for clinicians to consider streamlined discharge plans for orthopaedic oncology patients to potentially reduce the risk of SSI. Level of Evidence: Prognostic Level II. See Instructions for Authors for a complete description of levels of evidence.

1 January 2024 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
AGAlex Guedes
Alex Guedes
RBRicardo Becker
Ricardo Becker
SNSuely Nakagawa
Suely Nakagawa
AGAparecida Aguiar Lima Guedes
Aparecida Aguiar Lima Guedes
On the right and left sides of the thyroid, the parathyroid glands are presented in the form of four nodules in total, two apical and two basal1 1 Próspero JD, Baptista PPR, Amary MFC, Santos PPC. Paratireóides: estrutura, funções e patologia. Acta Ortop Bras. 2008;17(2):53-7. https://doi.org/10.1590/S1413-78522009000200011 https://doi.org/10.1590/S1413-7852200900... . Topographic variations are common—the parathyroid glands can be located near the larynx or even in the mediastinum, near the thymus1 1 Próspero JD, Baptista PPR, Amary MFC, Santos PPC. Paratireóides: estrutura, funções e patologia. Acta Ortop Bras. 2008;17(2):53-7. https://doi.org/10.1590/S1413-78522009000200011 https://doi.org/10.1590/S1413-7852200900... . Microscopically, they are made up of two main types of cells, clear and oxyphilic; the former secrete parathyroid hormone (PTH), and the latter have a still obscure function—all are arranged in a chordonal arrangement, interspersed with lobes of fatty tissue1 1 Próspero JD, Baptista PPR, Amary MFC, Santos PPC. Paratireóides: estrutura, funções e patologia. Acta Ortop Bras. 2008;17(2):53-7. https://doi.org/10.1590/S1413-78522009000200011 https://doi.org/10.1590/S1413-7852200900... ,2 2 Jambeiro JES, Guedes A, Mattos ESR, Guedes AAL, Freire ANM, Freire MDM, et al. Osteíte fibrose cística. Rev Cient HSI. 2023;7(1):18-30. .

1 January 2024 in Acta Ortopedica Brasileira
Verified
Journal Article
Open access
PDF file
RBRicardo Becker
Ricardo Becker
CGCarlos Roberto Galia
Carlos Roberto Galia
JPJulie Francine Cerutti Santos Pestilho
Julie Francine Cerutti Santos Pestilho
BABruno Pereira Antunes
Bruno Pereira Antunes
ABAndré Mathias Baptista
André Mathias Baptista
AGAlex Guedes
Alex Guedes
Introduction: Giant cell tumor of bone (GCTB) mainly affects young adults’ long bone epiphyses, threatening bone strength and joint function. Surgery is the primary treatment, although post-surgery recurrence is significant. This study analyzes patient profiles, treatments, and outcomes for GCTB in Brazil. Methods: We retrospectively assessed local recurrence, metastasis, and treatment approaches in 643 GCTB patients across 16 Brazilian centers (1989-2021), considering regional differences. Results: 5.1% (n=33) developed pulmonary metastases, 14.3% (n=92) had pathological fractures, and the local recurrence rate was 18.2% (n=114). Higher rates of pulmonary metastases (12.1%) and advanced tumors (Campanacci III, 88.9%) were noted in lower-income North and Northeast regions. The North also had more pathological fractures (33.3%), extensive resections (61.1%), and amputations (27.8%). These regions faced longer surgical delays (36-39 days) than the South and Southeast (27-33 days). Conclusions: Our findings corroborate international data, underscoring regional disparities in Brazil that may lead to worse outcomes in disadvantaged areas. This highlights the need for improved orthopedic oncology care in Brazil’s economically and structurally challenged regions. Level of Evidence III; Retrospective Cohort.

1 January 2019 in Revista do Colégio Brasileiro de Cirurgiões
Verified
Journal Article
Open access
PDF file
BABruno Pereira Antunes
Bruno Pereira Antunes
RBRicardo Becker
Ricardo Becker
ABAndré Tesainer Brunetto
André Tesainer Brunetto
BPBruno Silveira Pavei
Bruno Silveira Pavei
CFCaroline Brunetto de Farias
Caroline Brunetto de Farias
CGCarlos Roberto Galia
Carlos Roberto Galia
RESUMO Objetivo: determinar a expressão de neurotrofinas e seus receptores tirosina quinases em pacientes com osteossarcoma (OS) e sua correlação com desfechos clínicos. Métodos: biópsias de tumores primários de pacientes com OS tratados em uma única instituição, consecutivamente, entre 2002 e 2015, foram analisados através de imuno-histoquímica para expressão de receptores de tirosina quinase A e B (TrKA e TrKB), fator de crescimento neural (NGF) e fator neurotrófico derivado do cérebro (BDNF). De forma independente, dois patologistas classificaram os marcadores de imuno-histoquímica como negativos (negativos e focais fracos) ou positivos (moderado focal/difuso ou forte focal/difuso). Resultados: foram analisados dados de 19 pacientes (10 do sexo feminino e 9 do masculino) com mediana de idade de 12 anos (5 a 17,3 anos). Dos tumores, 83,3% estavam localizados em membros inferiores e 63,2% dos pacientes eram metastáticos ao diagnóstico. A sobrevida global em cinco anos foi de 55,3%. BDNF foi positivo em 16 pacientes (84%) e NGF em 14 pacientes (73%). TrKA e TrKB apresentaram coloração positiva em quatro (21,1%) e oito (42,1%) pacientes, respectivamente. A análise de sobrevida não demonstrou diferença significativa entre receptores TrK e neurotrofinas. Conclusão: amostras de OS primário expressam neurotrofinas e receptores TrK através de imuno-histoquímica. Estudos futuros podem auxiliar na identificação do papel das mesmas na patogênese do OS e determinar se há possível correlação prognóstica.